Ivy Rx review

Ivy Rx’s current sermorelin product page says “From $179 (use varies),” while its homepage shows $175 and peptide index shows $225. NAD⁺ injection and nasal spray pages also start at $179. None establishes the selected supply or billing interval. The terms describe renewing self-pay subscriptions, and the refund page does not accept returns. Confirm a written quote before intake.

Ivy Rx is a telehealth practice operating as IVY RX PLLC from 111 NE 1st Street, 8th Floor #8564, Miami, Florida, with a LegitScript badge displayed in the footer. Its weight-loss line runs compounded GLP-1 injections, a microdose option, oral melts and brand-name Ozempic and Mounjaro. Its anti-aging line lists NAD⁺ injection at $179, an NAD⁺ nasal spray from $179 "(used daily)", glutathione injection at $179, glutathione nasal spray, B12 injection at $179, sermorelin from $179 on the current product page, versus $175 on the homepage and metformin. Its peptides page lists sermorelin at $225, BPC-157 at $129 and a gut peptide complex at $89; the BPC-157 product is a 500 mcg capsule that also appears in the supplements section, alongside methylene blue. Its own copy promises a free consultation and free delivery, and its NAD⁺ spray page states the same price at every dose.

Standard telehealth with a free consultation and a dose-independent price claim on the NAD⁺ spray page — the NAD⁺ spray page states "Same price at every dose", which is the structurally better arrangement, since where cost scales with dose, titrating upward can quietly double a monthly bill. The site says a clinician reviews each questionnaire the same day. A free consultation also removes the usual barrier to asking what something costs before committing, which matters here because of what is missing from the price list. The entity disclosure is real: a named PLLC with a street address, and the LegitScript badge is displayed rather than merely claimed. Two things are not published. No state list appears on the site, so treat eligibility as something to confirm at intake. And no compounding pharmacy is named; the site says only that treatments are compounded in state-licensed pharmacies compliant with 503B and USP <797> standards. The sermorelin page recommends an initial six-month course with quarterly check-ins, but no lab work is described in the default path before starting.

Sermorelin appears at $175 on the homepage, “From $179 (use varies)” on its product page and $225 on the peptide index. The product pages for both NAD⁺ injection and nasal spray show “From $179 (use varies).” These are starting displays without a public vial quantity, supply duration or renewal interval; none is a verified monthly rate. Self-pay subscriptions auto-renew under the terms and may be changed or canceled in the portal. The refund page says returns are not accepted. Ask for the selected dose, amount, first charge and refill timing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Medication is described as prepared by state-licensed US compounding pharmacies, none of them named, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. One catalog detail deserves attention before the evidence discussion: BPC-157 is sold here as a 500 mcg oral capsule at $129, listed on both the peptides page and the supplements page and described in supplement terms, while its product page also invites you to start a medical assessment. A buyer should know whether they are being prescribed a compounded medication or sold a supplement, because the rules differ. On the evidence, the products here span the full range. Sermorelin acts on the growth-hormone axis, a genuine and well-described mechanism, but the long-term human outcome data stays thin and no controlled trial demonstrates the body-composition or recovery results it is marketed for. Injected and intranasal NAD⁺ have no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and raise blood NAD⁺, a biomarker rather than a benefit. Injectable glutathione has essentially no controlled human outcome evidence. BPC-157 sits at the same low tier — its tissue-repair reputation comes from animal work and user reports, not human trials, and the product page's claim that it is "considered safe" has no human safety data behind it. Individual results vary.